Evidence map›Paper›PMID 41882102›Full record

ArticleOncogene2026

Loss of ABCA3 disrupts lipid balance and leads to AMPK-dependent suppression of SREBP1 in glioblastoma stem cells.

Jun-Kyum Kim, Min Gi Park, Seok Won Ham, Seunghyun Yoon, Sua Kim, Junseok Jang, Hyejin Kim, Nayoung Hong, Jong Min Park, Cheol Gyu Park and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Jun-Kyum Kim *Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Min Gi Park *Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Seok Won Ham *Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Seunghyun YoonDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Sua KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Junseok JangDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Hyejin KimMEDIFIC Inc., Hwaseong-si, Republic of Korea.
Nayoung HongDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Jong Min ParkMEDIFIC Inc., Hwaseong-si, Republic of Korea.
Cheol Gyu ParkDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Min Ji ParkDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-5958-7633
Sang-Hun ChoiDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Jung Yun KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Hee-Young JeonDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Sunyoung SeoDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Seon Yong LeeDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Yeri LeeResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Hee Jin ChoDepartment of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, Republic of Korea.
Minseo GwakDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Eun-Jung KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Kiyoung EunDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Yong Jae ShinInnovative Institute for Precision Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Do-Hyun NamDepartment of Neurosurgery, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Se Hoon KimDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-7516-7372
Seung Jun YooMEDIFIC Inc., Hwaseong-si, Republic of Korea.
Hyunggee KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea. hg-kim@korea.ac.kr.ORCID http://orcid.org/0000-0002-5164-1663

Funding

Ministry of Health and Welfare (Ministry of Health, Welfare and Family Affairs) HI14C3418Ministry of Health and Welfare (Ministry of Health, Welfare and Family Affairs) RS-2022-00166323National Research Foundation of Korea (NRF) 2016M3C7A1913844National Research Foundation of Korea (NRF) 2017M3A9A8031425National Research Foundation of Korea (NRF) 2020R1A2C2099669National Research Foundation of Korea (NRF) 2022M3E5F2019255National Research Foundation of Korea (NRF) RS-2023-00218838
6 · The paper itself

Abstract

Malignant cancers exhibit distinct lipid metabolic features that support tumor initiation and progression. Glioblastoma (GBM) is an aggressive brain tumor driven by GBM stem cells (GSCs), which are responsible for tumor development and therapy resistance. However, effective treatments targeting vulnerable metabolic pathways in GSCs have not yet been developed. Here, we demonstrate that the ATP-binding cassette transporter A3 (ABCA3) maintains lipid metabolic balance in GSCs. ABCA3 is highly expressed in GSCs, where lipid biosynthesis is particularly active. Knocking down ABCA3 significantly reduces cell growth, self-renewal, viability, and tumor growth after intracranial implantation. These changes are caused by a profound disruption of lipid metabolic balance, as demonstrated by RNA sequencing and liquid chromatography-time-of-flight mass spectrometry, which revealed widespread alterations in lipid metabolism genes and lipid composition. Mechanistically, ABCA3 knockdown inhibits sterol regulatory element-binding protein 1 (SREBP1) signaling by accumulating acylcarnitines (ACs) caused by phospholipid breakdown. The increased ACs induce the production of mitochondrial reactive oxygen species, which activate adenosine monophosphate-activated protein kinase (AMPK), resulting in the inhibition of SREBP1 signaling and reduced GSC fitness. Overall, these findings suggest that ABCA3 maintains lipid metabolic balance in GSCs, and disrupting this function triggers AMPK-dependent suppression of SREBP1 signaling.

Indexed as

AMP-Activated Protein KinasesATP-Binding Cassette TransportersBrain NeoplasmsGlioblastomaLipid MetabolismNeoplastic Stem CellsSterol Regulatory Element Binding Protein 1AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceSignal TransductionABCA3 protein, humanAMP-Activated Protein KinasesATP-Binding Cassette TransportersSREBF1 protein, humanSterol Regulatory Element Binding Protein 1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.